Related Experiment Videos
Single and multiple metachronous osteosarcoma tumors after therapy
Norman Jaffe1, Peggy Pearson, Alan W Yasko
1Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. njaffe@mdanderson.org
Cancer
|November 25, 2003
Summary
Metachronous osteosarcoma, a secondary cancer, can occur in pediatric survivors of conventional osteosarcoma. Early detection and meticulous follow-up are crucial for managing this rare but serious sequela.
Area of Science:
- Oncology
- Pediatric Oncology
- Skeletal Tumors
Background:
- Conventional osteosarcoma treatment can lead to secondary, or metachronous, tumors.
- Understanding the incidence and characteristics of these secondary tumors is vital for long-term survivor care.
Purpose of the Study:
- To determine the incidence of metachronous osteosarcoma in pediatric patients.
- To characterize the clinical and pathological features of these secondary tumors.
- To evaluate the outcomes for patients developing metachronous osteosarcoma.
Main Methods:
- Retrospective review of 270 pediatric patients (under 18) with conventional osteosarcoma.
- Confirmation of absence of pulmonary and skeletal metastases using imaging (chest radiographs, CT scans, bone scans).
Main Results:
- Eleven pediatric patients developed metachronous osteosarcoma.
- Primary tumors commonly involved the femur; secondary tumors appeared in various bones, sometimes multifocally.
- Most patients (10/11) did not have pulmonary metastases at diagnosis of the secondary tumor; survival varied, with some patients surviving 20-50+ months post-treatment.
Conclusions:
- Metachronous osteosarcoma is an important, recognized complication in long-term survivors of pediatric osteosarcoma.
- Potential genetic predispositions, including Li-Fraumeni syndrome and retinoblastoma history, are implicated.
- Close surveillance is essential for early detection and effective treatment of secondary osteosarcoma.